Announcing MaRS Impact Health 2024

Published on April 4, 2024

It’s official: MaRS Impact Health takes place on June 12 and June 13 — and you’re invited! Grab your tickets now to network and sit in on discussions with experts across digital health, medical devices and biotech.

RSVP at: marsdd.it/impacthealth24-yt

The post Announcing MaRS Impact Health 2024 appeared first on MaRS Discovery District.

Continue reading on website
Other news

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

April 3, 2024
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s clinical study (the “Study”) (NCT05322954) evaluating the safety and feasibility of

Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024

April 4, 2024
VICTORIA, BC, April 3, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that the Company's common shares have been approved for listing on the Nasdaq Capital Mark